HOME › Research Insight › New Product Launches, Licenses, and approvals are the Driving Factors for Veterinary/Animal Vaccines Market in 2016
New Product Launches, Licenses, and approvals are the Driving Factors for Veterinary/Animal Vaccines Market in 2016
The veterinary vaccines market is dominated by established players such as Zoetis Inc. (U.S.), Merck Animal Health (U.S.), Merial Inc. (Sanofi) (France), Boehringer Ingelheim (Germany), and Elanco Animal Health (U.S.).
New product launches and license securement are the most-preferred strategies adopted by key players in this market. From January 2013 to June 2016, product launches accounted for 47.6% of the total number of developments in the market. In the past three years, the market has witnessed more than 20 new product launches, licenses, and approvals by key players across different vaccine markets. Players such as Merck Animal Health, (U.S.), Merial, Inc. (France), Ceva Animal Health (France), Boehringer Ingelheim, Inc. (Germany), and Zoetis Inc. (Pfizer) (U.S.) adopted these strategies to enhance their product offerings, increase their market share, cater to customers’ demands, and consolidate their market presence.
Agreements, partnerships, and collaboration accounted for the second-largest share of 19.0% of the total developments in the veterinary vaccine market. Players such as Merck Animal Health, (U.S.), Bayer Animal Health (Germany), Ceva Animal Health (France), Merial Inc. (France), and Zoetis Inc. (Pfizer) (U.S.) adopted these strategies to enhance their geographic reach and product portfolios.
Among the top five players in the veterinary vaccines market, Zoetis Inc. (Pfizer) (U.S.) held the largest share in 2016. The company has focused on new product launches to maintain its position and generate higher revenues in the veterinary vaccines market. In the past three years, the company has added various new products in its portfolio, such as Avian Influenza Vaccine H5N1 subtype, Equivac HeV, Fostera PRRS vaccine, Porcine Epidemic Diarrhea Vaccine, Poluvac Bron GA08, and Georgia 08 Strain IBV Vaccine.
Merck Animal Health accounted for the second-largest share in the veterinary vaccines market in 2016. The company focuses on launching new products to strengthen its position in the veterinary vaccines market. Between January 2013 and June 2016, the company has launched a wide range of innovative products, such as RNA Particle (RP) Vaccine Platform, AQUAVAC PD3, PORCILIS PCV M Hyo, and Once PMH INvaccine.
Veterinary/Animal Vaccines Market Product (Porcine, (Companion-Canine), (Livestock-Bovine), Poultry, Aquaculture), Diseases (Rabies, FMD, Swine Influenza, Strangles, Furunculous), Technology (DNA, Recombinant, Inactivated, Conjugate) - Forecast to 2021
Markets and Markets
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune, Maharashtra 411013, India